Literature DB >> 6800651

Decreased cytotoxicity of cis-diamminedichloroplatinum(II) by alpha-difluoromethylornithine depletion of polyamines in 9L rat brain tumor cells in vitro.

S M Oredsson, D F Deen, L J Marton.   

Abstract

Before treatment with the cytotoxic drug cis-dichlorodiammineplatinum(II) (cis-platinum), 9L rat brain gliosarcoma cells grown in vitro were depleted of intracellular polyamines by alpha-difluoromethylornithine (DFMO; 10 mM, 48 hr), an enzyme-activated, irreversible inhibitor of the polyamine-synthetic enzyme ornithine decarboxylase. In contrast to studies that showed that the cytotoxicity of 1,3-bis (2-chloroethyl)-1-nitrosourea as measured by colony-forming efficiency is enhanced by DFMO depletion of intracellular polyamines, the cytotoxicity of cis-platinum was significantly decreased in polyamine-depleted 9L cells. At 10, 1, and 0.1% survival levels, the dose modification factors were 2.0 to 2.1. Addition of exogenous putrescine to polyamine-depleted 9L cells 24 hr before treatment with cis-platinum partially reversed this phenomenon. When 9L cells were treated either with DFMO and cis-platinum or with DFMO, putrescine, and cis-platinum for 1 hr, a time period that is too short for DFMO to affect intracellular polyamine levels, the cytotoxicity of cis-platinum was decreased, but to a significantly lesser extent than by the 48-hr DFMO pretreatment. Putrescine alone did not alter the cytotoxic effect of cis-platinum when administered either 24 or 1 hr before treatment. DFMO appears to affect cis-platinum cytotoxicity by two different mechanisms, the first mediated through polyamine depletion and the second through a direct interaction with cis-platinum.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6800651

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Effects of DFMO-induced polyamine depletion on human tumor cell sensitivity to antineoplastic DNA-crosslinking drugs.

Authors:  J Seidenfeld; K A Komar; M F Naujokas; A L Block
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 2.  The chemotherapeutic potential of polyamine antimetabolites.

Authors:  A N Kingsnorth
Journal:  Ann R Coll Surg Engl       Date:  1986-03       Impact factor: 1.891

3.  Comparison of cancer chemotherapeutic agents in asynchronous and synchronous 9L cells.

Authors:  S D Henderson; B F Kimler; M L Barnes
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

4.  Influence of cis-dichlorodiamineplatinum on glioma cell morphology and cell cycle kinetics in tissue culture.

Authors:  V Mares; P A Giordano; G Mazzini; V Lisá; C Pellicciari; E Scherini; G Bottiroli; J Drobnik
Journal:  Histochem J       Date:  1987-04

5.  Contradictory antitumor efficacies produced by the combination of DNA attacking drugs and polyamine antimetabolites.

Authors:  R D Shrestha; S Fujimoto; K Okui
Journal:  Jpn J Surg       Date:  1987-07

Review 6.  DNA topoisomerase II as a target of antineoplastic drug therapy.

Authors:  L A Zwelling
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

7.  Polyamines in clinical disorders.

Authors:  D F Tierney; L J Marton; A D Hacker; N Lowe
Journal:  West J Med       Date:  1985-01

8.  Putrescine metabolism in human brain tumors.

Authors:  S S Goldman; N D Volkow; J Brodie; E S Flamm
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

9.  Effects of alpha-difluoromethylornithine on initiation and promotion of urinary bladder carcinogenesis in a heterotopically transplanted rat urinary bladder.

Authors:  K Rinsho; K Uchida; S Samma; R Oyasu
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

10.  Changes in mitochondrial structure and function in 9l rat brain tumor cells treated in vitro with alpha-difluoromethylornithine, a polyamine biosynthesis inhibitor.

Authors:  S M Oredsson; D S Friend; L J Marton
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.